Down-regulation of epidermal growth factor receptor by curcumin-induced UBE1L in human bronchial epithelial cells

Journal of Nutritional Biochemistry

Volumn 25, Issue 2, 2014, Pages 241-249

  Jiang, A Pei ^a   Zhou, Dong Hu ^a   Meng, Xu Lian ^a   Zhang, Ai Ping ^b   Zhang, Cui ^b   Li, Xiao Ting ^a   Feng, Qing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Curcumin; Down regulation; EGFR; UBE1L

Indexed keywords

CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRONCHUS; CANCER CELL CULTURE; CANCER TISSUE; CELL MEMBRANE; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

CURCUMIN; DOWN-REGULATION; EGFR; UBE1L;

BASE SEQUENCE; BRONCHI; CELL LINE; DNA PRIMERS; DOWN-REGULATION; EPITHELIAL CELLS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84892521186     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.11.001     Document Type: Article

References (46)

1. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004, 9:58-67.
2. Suzuki S., Dobashi Y., Sakurai H., Nishikawa K., Hanawa M., Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 2005, 103:1265-1273.
3. Riese D.N., Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998, 20:41-48.
4. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
5. Goswami A., Ranganathan P., Rangnekar V.M. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 2006, 66:2889-2892.
6. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005, 102:3788-3793.
7. Kane L.P., Shapiro V.S., Stokoe D., Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999, 9:601-604.
8. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002, 2:664-674.
9. Akca H., Demiray A., Tokgun O., Yokota J. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells. Lung Cancer-J Iaslc 2011, 73:302-309.
10. Waterman H., Katz M., Rubin C., Shtiegman K., Lavi S., Elson A., et al. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 2002, 21:303-313.
11. Johannessen L.E., Pedersen N.M., Pedersen K.W., Madshus I.H., Stang E. Activation of the epidermal growth factor (EGF) receptor induces formation of EGF receptor- and Grb2-containing clathrin-coated pits. Mol Cell Biol 2006, 26:389-401.
12. Haglund K., Sigismund S., Polo S., Szymkiewicz I., Di Fiore P.P., Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 2003, 5:461-466.
13. Mizuno E., Iura T., Mukai A., Yoshimori T., Kitamura N., Komada M. Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes. Mol Biol Cell 2005, 16:5163-5174.
14. Yuan W., Krug R.M. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 2001, 20:362-371.
15. Haas A.L., Ahrens P., Bright P.M., Ankel H. Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem 1987, 262:11315-11323.
16. Kok K., Hofstra R., Pilz A., van den Berg A., Terpstra P., Buys C.H., et al. A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc Natl Acad Sci U S A 1993, 90:6071-6075.
17. McLaughlin P.M., Helfrich W., Kok K., Mulder M., Hu S.W., Brinker M.G., et al. The ubiquitin-activating enzyme E1-like protein in lung cancer cell lines. Int J Cancer 2000, 85:871-876.
18. Feng Q., Sekula D., Guo Y., Liu X., Black C.C., Galimberti F., et al. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 2008, 7:3780-3788.
19. Shah S.J., Blumen S., Pitha-Rowe I., Kitareewan S., Freemantle S.J., Feng Q., et al. UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. Mol Cancer Ther 2008, 7:905-914.
20. Lin J.K. Molecular targets of curcumin. Adv Exp Med Biol 2007, 595:227-243.
21. Nagaraju G.P., Aliya S., Zafar S.F., Basha R., Diaz R., El-Rayes B.F. The impact of curcumin on breast cancer. Integr Biol (Camb) 2012, 4:996-1007.
22. Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B., Aggarwal B.B. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008, 267:133-164.
23. Chen A., Xu J., Johnson A.C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006, 25:278-287.
24. Yu S., Shen G., Khor TO, Kim J.H., Kong A.N. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 2008, 7:2609-2620.
25. Aggarwal S., Takada Y., Singh S., Myers J.N., Aggarwal B.B. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 2004, 111:679-692.
26. Squires M.S., Hudson E.A., Howells L., Sale S., Houghton C.E., Jones J.L., et al. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol 2003, 65:361-376.
27. Bharti A.C., Donato N., Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003, 171:3863-3871.
28. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9:671-675.
29. Dorai T., Gehani N., Katz A. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 2000, 4:1-6.
30. Lee J.Y., Lee Y.M., Chang G.C., Yu S.L., Hsieh W.Y., Chen J.J., et al. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PLoS One 2011, 6:e23756.
31. Chadalapaka G., Jutooru I., Burghardt R., Safe S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 2010, 8:739-750.
32. de Veer M.J., Holko M., Frevel M., Walker E., Der S., Paranjape J.M., et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001, 69:912-920.
33. Normanno N., Bianco C., De Luca A., Maiello M.R., Salomon D.S. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003, 10:1-21.
34. Malakhov M.P., Malakhova O.A., Kim K.I., Ritchie K.J., Zhang D.E. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002, 277:9976-9981.
35. Duex J.E., Sorkin A. RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis. Mol Biol Cell 2009, 20:1833-1844.
36. Gui A., Kobayashi A., Motoyama H., Kitazawa M., Takeoka M., Miyagawa S. Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells. BMC Cancer 2012, 12:179.
37. Binion D.G., Heidemann J., Li M.S., Nelson V.M., Otterson M.F., Rafiee P. Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am J Physiol Gastrointest Liver Physiol 2009, 297:G259-G268.
38. Kim K.I., Malakhova O.A., Hoebe K., Yan M., Beutler B., Zhang D.E. Enhanced antibacterial potential in UBP43-deficient mice against Salmonella typhimurium infection by up-regulating type I IFN signaling. J Immunol 2005, 175:847-854.
39. Jeon Y.J., Jo M.G., Yoo H.M., Hong S.H., Park J.M., Ka S.H., et al. Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. J Clin Invest 2012, 122:2622-2636.
40. Si X., Wang Y., Wong J., Zhang J., McManus B.M., Luo H. Dysregulation of the ubiquitin-proteasome system by curcumin suppresses coxsackievirus B3 replication. J Virol 2007, 81:3142-3150.
41. Rechtman M.M., Har-Noy O., Bar-Yishay I., Fishman S., Adamovich Y., Shaul Y., et al. Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha. FEBS Lett 2010, 584:2485-2490.
42. Zhang D., Zhang D.E. Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res 2011, 31:119-130.
43. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
44. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
45. Sorkin A., Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 2002, 3:600-614.
46. Berg M., Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 2012, 14:207-214.